Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions
Typical And Atypical Biotech Stock Responses
Executive Summary
Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.
You may also be interested in...
Stock Watch: Hierarchies Of Drugs Against The Same Target
Rarely does the best-selling product emerge when a newer antibody platform is used to improve on a successful earlier-generation product. Better to play to the platform’s strengths.
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.
Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?